Cooperative network France-Spain for the analysis of protein homeostasis and the development of personalized therapies for cancers (Q4294896): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Haute-Garonne / rank | |||
Normal rank | |||
Revision as of 09:58, 17 June 2022
Project Q4294896 in France, Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cooperative network France-Spain for the analysis of protein homeostasis and the development of personalized therapies for cancers |
Project Q4294896 in France, Spain |
Statements
939,843.45 Euro
0 references
1,445,912.88 Euro
0 references
65.0 percent
0 references
1 June 2019
0 references
31 May 2022
0 references
Fundación Privada Instituto de Investigación Oncológica Vall d'Hebron
0 references
41°23'28.50"N, 2°9'34.85"E
0 references
41°23'57.77"N, 2°8'32.32"E
0 references
41°25'43.28"N, 2°8'14.89"E
0 references
43°36'56.84"N, 1°23'53.92"E
0 references
43°17'36.82"N, 2°52'9.59"W
0 references
43°33'44.35"N, 1°28'49.58"E
0 references
41°24'11.34"N, 2°7'11.57"E
0 references
The goal of PROTEOblood is to optimize, to share and to exploit a set of state-of-the art technologies and resources through the coordination of academic and private partners of different POCTEFA territories, for the study of protein homeostasis in two prevalent subtypes of leukemia and lymphoma. PROTEOblood will generate innovative tools and technologies transferable to the development of personalized medicines against these diseases. We will establish a collection of patient-derived study models (organoids and xenografts) with the ability to recreate ex vivo the tumor micro-environment. Then, avant-garde proteomic approaches, associated with the analysis of system biology and the design of small molecules, will allow the complete characterization of proteinopathies, and the development of efficient and safe therapies that will be validated in the collections of organoids and xenografts. PROTEOblood will thus promote technological development, cross-border cooperation and the exchange of knowledge, facilitating the optimization of infrastructures and existing resources. Since the partners of PROTEOblood possess complementary capabilities illustrated by previous co-authorship in publications, patents and licenses, this project will undoubtedly increase the competitiveness and internationalization of the POCTEFA regions. (English)
0 references